GSK3B and Alzheimer disease: Except the changes in GSK3β activity and tau pT231 phosphorylation levels, the abnormal deposition of Aβ produced by the sequential cleavage of β-site AβPP-cleaving enzyme (BACE1) and γ-secretase from AβPP is a major pathological feature of AD [32].